BDA advise on EpiPen supply disruption

Practices are urged to renew anaphylaxis kits with adrenaline ampoules not AAIs

The Chief Dental Officer for England has written to dentists in response to the disruption in the supply of EpiPen and EpiPen Junior adrenaline auto-injectors (AAIs).

Practices are requested that, when they renew the adrenaline in their anaphylaxis kits they order ampoules, ensuring this includes dosing charts, needles and syringes, and not AAIs. This will reduce the reliance on AAIs and preserve essential EpiPen stocks for patients, parents, carers, teachers, who as lay persons cannot be expected to administer adrenaline via a needle and syringe.

Supplies of adrenaline ampoules are currently available and there is an expectation that dental practitioners should use these in preference to the EpiPen or similar devices.

The Green Book and Resus Council guidance provides additional advice to healthcare professionals on the use of adrenaline in response to anaphylaxis.

All enquiries relating to this issue should be sent to the DH Supply Resilience Team at [email protected]

BDA advisory services

The BDA’s advisory services team offers advice to BDA members on a huge range of issues, such as employment law, health and safety, the NHS, business support and regulatory inspections. They also provide employment representation, an associate contract-checking service, mediation services, tribunal support and consultancy services.

Become a Dentistry Online member

Become a member
Register for webinar
"Company" would like to send you relevant email communications to this webinar, by opting in to receive these emails you are agreeing to be sent email communications by "Company".
You can opt-out at any time.
Add to calendar